Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $237.41 | 15 | 76.6% |
| Unspecified | $72.50 | 1 | 23.4% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $72.50 | 1 | $0 (2020) |
| Pharmacyclics LLC, An AbbVie Company | $37.86 | 2 | $0 (2018) |
| EMD Serono, Inc. | $36.21 | 2 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $30.14 | 2 | $0 (2020) |
| Incyte Corporation | $29.54 | 2 | $0 (2021) |
| Genentech USA, Inc. | $26.99 | 2 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $20.27 | 1 | $0 (2018) |
| Amgen Inc. | $16.60 | 1 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $14.39 | 1 | $0 (2017) |
| Foundation Medicine, Inc. | $13.53 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $46.53 | 3 | Incyte Corporation ($18.05) |
| 2020 | $89.99 | 2 | Eli Lilly and Company ($72.50) |
| 2018 | $136.24 | 8 | Pharmacyclics LLC, An AbbVie Company ($37.86) |
| 2017 | $37.15 | 3 | E.R. Squibb & Sons, L.L.C. ($14.39) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/27/2021 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $11.88 | General |
| Category: ONCOLOGY | ||||||
| 04/26/2021 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: Hematology | ||||||
| 04/12/2021 | Incyte Corporation | JAKAFI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $18.05 | General |
| Category: Hematology/Oncology | ||||||
| 12/08/2020 | Eli Lilly and Company | — | — | In-kind items and services | $72.50 | Research |
| Study: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED PHASE II STUDY OF ENZALUTAMIDE WITH OR WITHOUT THE PI3 KINASE-MTOR INHIBITOR LY3023414 IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER | ||||||
| 03/09/2020 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $17.49 | General |
| 08/30/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: Oncology | ||||||
| 08/23/2018 | EMD Serono, Inc. | Bavencio (Biological) | Food and Beverage | In-kind items and services | $20.34 | General |
| Category: Oncology | ||||||
| 07/12/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $18.63 | General |
| Category: Oncology | ||||||
| 07/11/2018 | Genentech USA, Inc. | VENCLEXTA (Biological) | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: BioOncology | ||||||
| 07/10/2018 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONONE HEME, FOUNDATIONONE CDX | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: ONCOLOGY | ||||||
| 07/03/2018 | Merck Sharp & Dohme Corporation | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $12.65 | General |
| Category: ONCOLOGY | ||||||
| 06/21/2018 | Teva Pharmaceuticals USA, Inc. | BENDEKA (Drug) | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: Oncology | ||||||
| 02/15/2018 | EMD Serono, Inc. | Bavencio (Biological) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: Oncology | ||||||
| 12/04/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $11.49 | General |
| Category: Hematology/Oncology | ||||||
| 10/10/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.39 | General |
| Category: Oncology | ||||||
| 09/05/2017 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $11.27 | General |
| Category: BioOncology/Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED PHASE II STUDY OF ENZALUTAMIDE WITH OR WITHOUT THE PI3 KINASE-MTOR INHIBITOR LY3023414 IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER | Eli Lilly and Company | $72.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 4 | 111 | 127 | $21,727 | $6,461 |
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 51 | 51 | $15,912 | $4,740 | 29.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 20 | 22 | $4,708 | $1,430 | 30.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 20 | 27 | $864.00 | $209.79 | 24.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 20 | 27 | $243.00 | $81.00 | 33.3% |
About Dr. Nadim Nimeh, M.D
Dr. Nadim Nimeh, M.D is a Hematology & Oncology healthcare provider based in Lawton, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275512915.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nadim Nimeh, M.D has received a total of $309.91 in payments from pharmaceutical and medical device companies, with $46.53 received in 2021. These payments were reported across 16 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($237.41).
As a Medicare-enrolled provider, Nimeh has provided services to 111 Medicare beneficiaries, totaling 127 services with total Medicare billing of $6,461. Data is available for 1 year (2021–2021), covering 4 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Lawton, OK
- Active Since 01/11/2006
- Last Updated 01/27/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1275512915
Products in Payments
- Imbruvica (Drug) $37.86
- Bavencio (Biological) $36.21
- JAKAFI (Drug) $29.54
- BENDEKA (Drug) $20.27
- Nplate (Biological) $16.60
- VENCLEXTA (Biological) $15.72
- OPDIVO (Biological) $14.39
- FOUNDATIONONE (Device) $13.53
- LYNPARZA (Biological) $12.65
- ZEJULA (Drug) $11.88
- Rituxan (Biological) $11.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.